Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?

Redjoul R, Robin C, Foulet F, Leclerc M, Beckerich F, Cabanne L, di Blasi R, Pautas C, Toma A, Botterel F, Maury S, Cordonnier C.

Bone Marrow Transplant. 2018 Nov 9. doi: 10.1038/s41409-018-0391-2. [Epub ahead of print]

PMID:
30413810
2.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S.

Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3.

3.

De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome.

la Martire G, Robin C, Oubaya N, Lepeule R, Beckerich F, Leclerc M, Barhoumi W, Toma A, Pautas C, Maury S, Akrout W, Cordonnier-Jourdin C, Fihman V, Venditti M, Cordonnier C.

Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1931-1940. doi: 10.1007/s10096-018-3328-1. Epub 2018 Jul 26.

PMID:
30051357
4.

Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients.

Robin C, Hémery F, Dindorf C, Thillard J, Cabanne L, Redjoul R, Beckerich F, Rodriguez C, Pautas C, Toma A, Maury S, Durand-Zaleski I, Cordonnier C.

BMC Infect Dis. 2017 Dec 5;17(1):747. doi: 10.1186/s12879-017-2854-2.

5.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau É, Dumesnil C, Guillaume T, Huynh A, Levrat SM, Menard AL, Michallet M, Pautas C, Poiré X, Ravinet A, Yakoub-Agha I, Bazarbachi A.

Bull Cancer. 2017 Dec;104(12S):S84-S98. doi: 10.1016/j.bulcan.2017.05.009. Epub 2017 Nov 26. Review. French.

PMID:
29179894
6.

Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients.

Hurabielle C, Sbidian E, Beltraminelli H, Bouchindhomme B, Chassagne-Clément C, Balme B, Bossard C, Delfau-Larue MH, Wolkenstein P, Chosidow O, Cordonnier C, Toma A, Pautas C, Ortonne N.

Hum Pathol. 2018 Jan;71:100-108. doi: 10.1016/j.humpath.2017.10.018. Epub 2017 Oct 28.

PMID:
29107664
7.

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.

Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau E, Dumesnil C, Guillaume T, Huynh A, Masouridi Levrat S, Menard AL, Pautas C, Poiré X, Ravinet A, Michallet M, Bazarbachi A.

Curr Res Transl Med. 2017 Apr - Jun;65(2):65-69. doi: 10.1016/j.retram.2017.06.001. Epub 2017 Jul 4. Review.

PMID:
28687223
8.

Molecular Demonstration of a Pneumocystis Outbreak in Stem Cell Transplant Patients: Evidence for Transmission in the Daycare Center.

Robin C, Alanio A, Gits-Muselli M, la Martire G, Schlemmer F, Botterel F, Angebault C, Leclerc M, Beckerich F, Redjoul R, Pautas C, Toma A, Maury S, Bretagne S, Cordonnier C.

Front Microbiol. 2017 Apr 24;8:700. doi: 10.3389/fmicb.2017.00700. eCollection 2017.

9.

Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.

Ghoufi L, Ortonne N, Ingen-Housz-Oro S, Barhoumi W, Begon E, Haioun C, Pautas C, Beckerich F, Robin C, Wolkenstein P, Cordonnier C, Chosidow O, Toma A.

Medicine (Baltimore). 2016 Apr;95(15):e3033. doi: 10.1097/MD.0000000000003033.

10.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

11.

Profound lymphopenia is associated with a lower risk of hepatic cytolysis during antithymocyte globulin administration.

Al Dweik B, Redjoul R, Bastuji-Garin S, Beckerich F, Robin C, Pautas C, Toma A, Cabanne L, Maury S, Cordonnier C.

Am J Hematol. 2016 Jun;91(4):E276-8. doi: 10.1002/ajh.24309. No abstract available.

12.

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N; French AML Intergroup.

Haematologica. 2016 Mar;101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3.

13.

Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease.

Delbos F, Barhoumi W, Cabanne L, Beckerich F, Robin C, Redjoul R, Astati S, Toma A, Pautas C, Ansart-Pirenne H, Cordonnier C, Bierling P, Maury S.

Biol Blood Marrow Transplant. 2016 Feb;22(2):292-299. doi: 10.1016/j.bbmt.2015.09.027. Epub 2015 Nov 11.

14.

Severe chronic primary neutropenia in adults: report on a series of 108 patients.

Sicre de Fontbrune F, Moignet A, Beaupain B, Suarez F, Galicier L, Socié G, Varet B, Coppo P, Michel M, Pautas C, Oksenhendler E, Lengline E, Terriou L, Moreau P, Chantepie S, Casadevall N, Michot JM, Gardembas M, Michallet M, Croisille L, Audrain M, Bellanné-Chantelot C, Donadieu J, Lamy T; French Severe Chronic Neutropenia Registry.

Blood. 2015 Oct 1;126(14):1643-50. doi: 10.1182/blood-2015-03-634493. Epub 2015 Aug 10.

15.

Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.

Khaznadar Z, Boissel N, Agaugué S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, Preudhomme C, Dombret H, Dulphy N, Toubert A.

J Immunol. 2015 Sep 15;195(6):2580-90. doi: 10.4049/jimmunol.1500262. Epub 2015 Aug 5.

16.

Risk factors and scoring system for predicting bacterial resistance to cefepime as used empirically in haematology wards.

El Maaroufi H, Goubard A, Redjoul R, Legrand P, Pautas C, Mikdame M, Doghmi K, Toma A, Maury S, Schwarzinger M, Cordonnier C.

Biomed Res Int. 2015;2015:945769. doi: 10.1155/2015/945769. Epub 2015 May 5.

17.

Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice.

Wolfromm A, Rodriguez C, Michel M, Habibi A, Audard V, Benayoun E, Rogier O, Challine D, Chosidow O, Lelièvre JD, Chevalier X, Le Bras F, Pautas C, Imbert M, Pawlotsky JM, Wagner-Ballon O.

Br J Haematol. 2015 Jul;170(2):192-9. doi: 10.1111/bjh.13421. Epub 2015 Apr 28.

PMID:
25920561
18.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N.

Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.

19.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terré C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H.

Haematologica. 2015 May;100(5):e196-9. doi: 10.3324/haematol.2014.115576. Epub 2014 Dec 31. No abstract available.

20.

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Rahmé R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Adès L.

Leukemia. 2014 Dec;28(12):2422-4. doi: 10.1038/leu.2014.240. Epub 2014 Aug 21. No abstract available.

PMID:
25142818
21.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A.

Oncotarget. 2014 Aug 15;5(15):6280-8.

22.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N.

Blood. 2014 Aug 21;124(8):1312-9. doi: 10.1182/blood-2014-01-549212. Epub 2014 Jul 8.

23.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.

Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C.

Oncotarget. 2014 Feb 28;5(4):916-32.

24.

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.

Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS).

Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6.

25.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillot D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S.

J Clin Oncol. 2014 Feb 1;32(4):297-305. doi: 10.1200/JCO.2013.50.2047. Epub 2013 Dec 16.

PMID:
24344214
26.

Outcome of older patients with acute myeloid leukemia in first relapse.

Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Fenaux P, Chevret S, Castaigne S, Dombret H.

Am J Hematol. 2013 Sep;88(9):758-64. doi: 10.1002/ajh.23498. Epub 2013 Aug 7.

27.

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillerm G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N.

Haematologica. 2013 Sep;98(9):1467-75. doi: 10.3324/haematol.2012.080895. Epub 2013 Mar 28.

28.

Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report.

Rahmé R, Benayoun E, Pautas C, Cordonnier C, Wagner-Ballon O, Maury S.

Exp Hematol. 2013 Jun;41(6):505-7. doi: 10.1016/j.exphem.2013.02.011. Epub 2013 Feb 24. No abstract available.

PMID:
23462143
29.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup.

Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.

30.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H.

J Clin Oncol. 2013 Jan 20;31(3):321-7. doi: 10.1200/JCO.2011.40.3642. Epub 2012 Dec 17.

PMID:
23248249
31.

A new workflow for the microbiological diagnosis of febrile neutropenia in patients with a central venous catheter.

Pautas C, Sbidian E, Hicheri Y, Bastuji-Garin S, Bretagne S, Corbel C, Gregoire L, Maury S, Merabet L, Cordonnier C, Cambau E.

J Antimicrob Chemother. 2013 Apr;68(4):943-6. doi: 10.1093/jac/dks462. Epub 2012 Nov 21.

PMID:
23171951
32.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Socié G, Michallet M, Castaigne S, Dombret H.

Leuk Res. 2012 Sep;36(9):1112-8. doi: 10.1016/j.leukres.2012.04.020. Epub 2012 May 28.

PMID:
22647869
33.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association.

Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Erratum in: Lancet. 2018 Feb 8;:.

PMID:
22482940
34.

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.

Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T, Terré C, Preudhomme C, Fenaux P, Michallet M, Socié G, Dombret H.

Bone Marrow Transplant. 2012 Nov;47(11):1436-41. doi: 10.1038/bmt.2012.49. Epub 2012 Mar 19.

PMID:
22426749
35.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
36.

Hemophagocytic syndrome after allogeneic hematopoietic cell transplantation: more a graft rejection than an infectious process?

Redjoul R, Toma A, Hicheri Y, El Maaroufi H, Maertens J, Vigouroux S, Lioure B, Machaczka M, Pautas C, Bories D, Wagner-Ballon O, Gaulard P, Martin-Garcia N, Maury S, Cordonnier C.

Eur J Haematol. 2012 May;88(5):458-60. doi: 10.1111/j.1600-0609.2012.01757.x. Epub 2012 Feb 14. No abstract available.

PMID:
22268532
37.

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial.

Cannas G, Pautas C, Raffoux E, Quesnel B, de Botton S, de Revel T, Reman O, Gardin C, Elhamri M, Boissel N, Fenaux P, Michallet M, Castaigne S, Dombret H, Thomas X.

Leuk Lymphoma. 2012 Jun;53(6):1068-76. doi: 10.3109/10428194.2011.636812. Epub 2012 Jan 31.

PMID:
22145959
38.

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.

Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S.

Am J Hematol. 2012 Jan;87(1):62-5. doi: 10.1002/ajh.22201. Epub 2011 Nov 10.

39.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C, Gardin C, Thomas X, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C.

Leukemia. 2011 Dec;25(12):1918-21. doi: 10.1038/leu.2011.173. Epub 2011 Jul 15. No abstract available.

PMID:
21760594
40.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terré C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H.

Blood. 2011 Aug 18;118(7):1754-62. doi: 10.1182/blood-2011-04-349258. Epub 2011 Jun 20.

41.

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terré C, Fenaux P, Castaigne S, Dombret H, Boissel N; Acute Leukemia French Association (ALFA).

Haematologica. 2011 Jun;96(6):837-44. doi: 10.3324/haematol.2010.036921. Epub 2011 Apr 1.

42.

Clofarabine as a potential stimulant of alloreactivity.

Atimere N, Zriba S, Hicheri Y, Pautas C, Cordonnier C, Maury S.

Bone Marrow Transplant. 2011 Oct;46(10):1393-4. doi: 10.1038/bmt.2010.309. Epub 2010 Dec 13. No abstract available.

PMID:
21151182
43.

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, Pautas C, Berthou C, Guyotat D, Cony-Makhoul P, Gardembas M, Michallet M, Hayette S, Cayuela JM, Weiss IR, Réa D, Castaigne S, Mahon FX, Guilhot F, Rousselot P.

Leuk Res. 2011 Jun;35(6):777-82. doi: 10.1016/j.leukres.2010.11.004. Epub 2010 Dec 10.

PMID:
21145590
44.

Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study.

Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, Cabanne L, Bretagne S, Cordonnier C.

Haematologica. 2011 Feb;96(2):337-41. doi: 10.3324/haematol.2010.030825. Epub 2010 Nov 11.

45.

Updated guidelines for managing fungal diseases in hematology patients.

Hicheri Y, Toma A, Maury S, Pautas C, Mallek-Kaci H, Cordonnier C.

Expert Rev Anti Infect Ther. 2010 Sep;8(9):1049-60. doi: 10.1586/eri.10.85. Review.

PMID:
20818948
46.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Boissel N, Nibourel O, Renneville A, Gardin C, Reman O, Contentin N, Bordessoule D, Pautas C, de Revel T, Quesnel B, Huchette P, Philippe N, Geffroy S, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C.

J Clin Oncol. 2010 Aug 10;28(23):3717-23. doi: 10.1200/JCO.2010.28.2285. Epub 2010 Jul 12.

PMID:
20625116
47.

Acute myeloid leukemia after infliximab: a case report.

Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P.

Clin Exp Rheumatol. 2009 Nov-Dec;27(6):999-1000.

PMID:
20149321
48.

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.

Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, Terre C, Gardin C, Hayette S, Preudhomme C, Dombret H.

Cancer. 2010 Apr 1;116(7):1725-32. doi: 10.1002/cncr.24943.

49.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S.

J Clin Oncol. 2010 Feb 10;28(5):808-14. doi: 10.1200/JCO.2009.23.2652. Epub 2010 Jan 4.

PMID:
20048183
50.

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

Renneville A, Boissel N, Gachard N, Naguib D, Bastard C, de Botton S, Nibourel O, Pautas C, Reman O, Thomas X, Gardin C, Terré C, Castaigne S, Preudhomme C, Dombret H.

Blood. 2009 May 21;113(21):5090-3. doi: 10.1182/blood-2008-12-194704. Epub 2009 Mar 16.

Supplemental Content

Loading ...
Support Center